Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Appendix
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Domínguez-Bendala, J.
Right arrow Articles by Edlund, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Domínguez-Bendala, J.
Right arrow Articles by Edlund, H.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 54:720-726, 2005
© 2005 by the American Diabetes Association, Inc.

TAT-Mediated Neurogenin 3 Protein Transduction Stimulates Pancreatic Endocrine Differentiation In Vitro

Juan Domínguez-Bendala1, Dagmar Klein1, Melina Ribeiro1, Camillo Ricordi1, Luca Inverardi1, Ricardo Pastori1, and Helena Edlund1,2

1 Diabetes Research Institute, University of Miami School of Medicine, Miami, Florida
2 Umeå Center for Molecular Medicine, Umeå University, Umeå, Sweden

Stem cell technologies hold great potential for the treatment of type 1 diabetes, provided that functional transplantable ß-cells can be selectively generated in an efficient manner. Such a process should recapitulate, at least to a certain extent, the embryonic development of ß-cells in vitro. However, progress at identifying the transcription factors involved in ß-cell development has not been accompanied by a parallel success at unraveling the pattern of their instructive extracellular signals. Here we present proof of principle of a novel approach to circumvent this problem, based on the use of the HIV/TAT protein transduction domain. Neurogenin 3 (ngn3), a factor whose expression is essential for pancreatic endocrine differentiation, was fused to the TAT domain. Administration of TAT/ngn3 to cultured pancreatic explants results in efficient uptake, nuclear translocation, and stimulation of downstream reporter and endogenous genes. Consistent with the predicted activity of the protein, e9.5 and e13.5 mouse pancreatic explants cultured in the presence of TAT/ngn3 show an increased level of endocrine differentiation compared with control samples. Our results raise the possibility of sequentially specifying stem/progenitor cells toward the ß-cell lineage, by using the appropriate sequence and combination of TAT-fused transcription factors.

Address correspondence and reprint requests to Helena Edlund, Diabetes Research Institute, University of Miami School of Medicine, 1450 NW 10th Ave., Miami, FL 33136. E-mail: helena.edlund{at}med.miami.edu or helena.edlund{at}ucmm.umu.se


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 PhysiologyHome page
S. P. Raikwar, T. Mueller, and N. Zavazava
Strategies for Developing Therapeutic Application of Human Embryonic Stem Cells
Physiology, February 1, 2006; 21(1): 19 - 28.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.